BR112023019795A2 - Composições nasais compreendendo alcaftadina - Google Patents

Composições nasais compreendendo alcaftadina

Info

Publication number
BR112023019795A2
BR112023019795A2 BR112023019795A BR112023019795A BR112023019795A2 BR 112023019795 A2 BR112023019795 A2 BR 112023019795A2 BR 112023019795 A BR112023019795 A BR 112023019795A BR 112023019795 A BR112023019795 A BR 112023019795A BR 112023019795 A2 BR112023019795 A2 BR 112023019795A2
Authority
BR
Brazil
Prior art keywords
alcaftadine
nasal
nasal compositions
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
BR112023019795A
Other languages
English (en)
Inventor
Akhilesh Sharma
Amol Aiwale
Babasaheb Aware
Viraj Shah
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of BR112023019795A2 publication Critical patent/BR112023019795A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições nasais compreendendo alcaftadina. a presente invenção refere-se a uma composição farmacêutica nasal compreendendo alcaftadina ou um sal farmaceuticamente aceitável da mesma e, opcionalmente, um ou mais excipientes, métodos farmaceuticamente aceitáveis de tratamento de rinite alérgica, rinoconjutivite alérgica ou sintomas das mesmas (tais como congestão nasal) com a composição farmacêutica nasal, e métodos de preparar a mesma.
BR112023019795A 2021-04-01 2021-06-14 Composições nasais compreendendo alcaftadina BR112023019795A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121015680 2021-04-01
PCT/IB2021/055221 WO2022208146A1 (en) 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine

Publications (1)

Publication Number Publication Date
BR112023019795A2 true BR112023019795A2 (pt) 2023-11-07

Family

ID=76523258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019795A BR112023019795A2 (pt) 2021-04-01 2021-06-14 Composições nasais compreendendo alcaftadina

Country Status (11)

Country Link
US (1) US20240173331A1 (pt)
EP (1) EP4312973A1 (pt)
JP (1) JP2024512121A (pt)
KR (1) KR20230163413A (pt)
CN (1) CN117120029A (pt)
AU (1) AU2021437358A1 (pt)
BR (1) BR112023019795A2 (pt)
CA (1) CA3213156A1 (pt)
CL (1) CL2023002871A1 (pt)
MX (1) MX2023011546A (pt)
WO (1) WO2022208146A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992493B1 (en) * 2022-10-25 2024-05-28 Liangdan Sun Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053678T3 (es) 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
SI1919450T1 (sl) 2005-09-01 2014-10-30 Meda Ab Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
EA016221B1 (ru) * 2006-03-31 2012-03-30 ВИСТЭКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмические композиции и способ лечения аллергических заболеваний глаз
AU2012275113A1 (en) * 2011-06-29 2014-01-30 Allergan, Inc. Alcaftadine for use in the treatment of urticaria
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
WO2019022225A1 (ja) 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
WO2021255622A1 (en) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid

Also Published As

Publication number Publication date
AU2021437358A1 (en) 2023-09-14
MX2023011546A (es) 2023-10-06
JP2024512121A (ja) 2024-03-18
EP4312973A1 (en) 2024-02-07
CL2023002871A1 (es) 2024-01-26
US20240173331A1 (en) 2024-05-30
CN117120029A (zh) 2023-11-24
CA3213156A1 (en) 2022-10-06
KR20230163413A (ko) 2023-11-30
WO2022208146A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
NI201900119A (es) Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
BR112022024840A2 (pt) Combinação de alcaftadina e um corticosteroide
BR112017011552A2 (pt) derivados de fgf21 e seu uso
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
BR112021021284A2 (pt) Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112023019795A2 (pt) Composições nasais compreendendo alcaftadina
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
BR112022012684A2 (pt) Compostos cíclicos e métodos de uso dos mesmos